Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Roxane Hillier, EURETINA 2022: Mechanisms of action in rhegmatogenous retinal detachment repair (Part 2)

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 20th 2022

In this touchOPHTHALMOLOGY interview, Roxane Hillier (Newcastle Eye Centre, Newcastle, UK) discussed techniques involved in retinal reattachment and shared the highlights from her EURETINA course on rhegmatogenous retinal detachment repair.

The instructional course entitled “Mechanisms of Action in Rhegmatogenous Retinal Detachment Repair” was conducted at EURETINA 2022, 1–4 September 2022 

  1. Could you tell us a little about the mechanisms of retinal reattachment with scleral buckle and pneumatic retinopexy? (00:13)
  2. What modifications in techniques can improve the integrity of reattachment? (01:10)
  3. What were the key take home messages of the course you presented at EURETINA? (03:19)

Disclosure: Roxane Hillier has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.

Filmed as a highlight of EURETINA 2022.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup